Citation Impact
Citing Papers
Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma
2007 Standout
Cancer and Altered Metabolism: Potential Importance of Hypoxia-Inducible Factor and 2-Oxoglutarate-Dependent Dioxygenases
2011 StandoutNobel
Resistance to tamoxifen‐induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer
2001
SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients
2009
Hypoxia — a key regulatory factor in tumour growth
2002 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Roles of p53, Myc and HIF-1 in Regulating Glycolysis — the Seventh Hallmark of Cancer
2008
Angiogenesis: from plants to blood vessels
2006 Standout
Honey, Propolis, and Royal Jelly: A Comprehensive Review of Their Biological Actions and Health Benefits
2017 Standout
Nutraceuticals: Facts and fiction
2007 Standout
Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies
2005 Standout
Absorption, tissue distribution and excretion of pelargonidin and its metabolites following oral administration to rats
2006
Review article: the role of butyrate on colonic function
2007 Standout
Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
2012 Standout
The β-Thalassemias
1999 Standout
Dietary Intake and Bioavailability of Polyphenols
2000 Standout
Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia
1995 Standout
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice
2002 StandoutNobel
The chemical chaperone 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response
2009
10‐Hydroxy‐2‐decenoic Acid, a Major Fatty Acid from Royal Jelly, Inhibits VEGF‐Induced Angiogenesis in Human Umbilical Vein Endothelial Cells
2007
Otto Warburg's contributions to current concepts of cancer metabolism
2011 Standout
The human keratins: biology and pathology
2008 Standout
Targeting metabolic transformation for cancer therapy
2010
Histone deacetylases, transcriptional control, and cancer
2000
Post-therapy Serum Prostate-Specific Antigen Level and Survival in Patients With Androgen-Independent Prostate Cancer
1999
Differentiation therapy of human cancer: basic science and clinical applications
2001
Anticancer activities of histone deacetylase inhibitors
2006 Standout
The strawberry: Composition, nutritional quality, and impact on human health
2011 Standout
Dietary phenolics: chemistry, bioavailability and effects on health
2009 Standout
Citrus flavone tangeretin inhibits leukaemic HL-60 cell growth partially through induction of apoptosis with less cytotoxicity on normal lymphocytes
1995
Polymeric Proanthocyanidins Are Catabolized by Human Colonic Microflora into Low-Molecular-Weight Phenolic Acids
2000
Valproic Acid Inhibits Angiogenesis in Vitro and in Vivo
2004
Coumarins: Old Compounds with Novel Promising Therapeutic Perspectives
2010 Standout
Endoplasmic Reticulum Stress and the Inflammatory Basis of Metabolic Disease
2010 Standout
Histone deacetylases and cancer: causes and therapies
2001 Standout
Histone deacetylase as a therapeutic target
2001
Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships
2002 Standout
The Metastasis-associated Proteins 1 and 2 Form Distinct Protein Complexes with Histone Deacetylase Activity
2003
The Role of Phosphometabolites in Cell Proliferation, Energy Metabolism, and Tumor Therapy
1997
Sickle-cell disease
2010 Standout
Beyond Radioiodine: A Review of Potential New Therapeutic Approaches for Thyroid Cancer
2003
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium
2006 Standout
Butyrate and phenylacetate as differentiating agents: Practical problems and opportunities
1995
Sorghum phytochemicals and their potential impact on human health
2004 Standout
Histone deacetylase inhibitors suppress telomerase reverse transcriptase mrna expression in prostate cancer cells
2001
Role of histone deacetylases in acute leukemia
1998
Normal and Pathologic Concentrations of Uremic Toxins
2012 Standout
Dysregulated pH: a perfect storm for cancer progression
2011 Standout
Cisplatin: The first metal based anticancer drug
2019 Standout
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
2001 Standout
Automated segmentation of tissue images for computerized IHC analysis
2010
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
2006 Standout
Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression
2001 StandoutNobel
Recent update on the PPARα-null mouse
1997
Intraperitoneal cisplatin‐based chemotherapy vs. intravenous cisplatin‐based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer
2001
FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity
2001 StandoutNobel
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
2001 Standout
Butyrate as a differentiating agent: pharmacokinetics, analogues and current status
1994
Phenylacetic Acid and Arterial Vascular Properties in Patients with Chronic Kidney Disease Stage 5 on Hemodialysis Therapy
2007
Dietary (Poly)phenolics in Human Health: Structures, Bioavailability, and Evidence of Protective Effects Against Chronic Diseases
2012 Standout
Histone Acetylation Modifiers in the Pathogenesis of Malignant Disease
2000
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
2006 Standout
Histone deacetylases (HDACs): characterization of the classical HDAC family
2003 Standout
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
2000
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.
2001
Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer
2005 Standout
Vitamin D3 analogs and their 24-Oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects
1997
Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate
1994
Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial
1995
Keratin 23 (K23), a novel acidic keratin, is highly induced by histone deacetylase inhibitors during differentiation of pancreatic cancer cells
2001
The Reciprocal Interactions between Polyphenols and Gut Microbiota and Effects on Bioaccessibility
2016 Standout
Update on Uses and Properties of Citrus Flavonoids: New Findings in Anticancer, Cardiovascular, and Anti-inflammatory Activity
2008 Standout
The PPARs: From Orphan Receptors to Drug Discovery
2000 Standout
Targeting excessive angiogenesis with functional foods and nutraceuticals
2003
Unravelling the conundrum of tannins in animal nutrition and health
2006 Standout
The Role of Vitamin D in Cancer Prevention
2005 Standout
The Effects of Plant Flavonoids on Mammalian Cells:Implications for Inflammation, Heart Disease, and Cancer
2000 Standout
Controls of Hair Follicle Cycling
2001 Standout
The Control of Prostate-Specific Antigen Expression and Gene Regulation by Pharmacological Agents
2001
THE MANY ROLES OF c-Myc IN APOPTOSIS
1998
Pt(iv ) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action
2016
Can We Prevent Prostate Cancer? Rationale and Current Status of Prostate Cancer Chemoprevention
2005
Stacked Sparse Autoencoder (SSAE) for Nuclei Detection on Breast Cancer Histopathology Images
2015 Standout
Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells.
1999
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
1998
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
2007 StandoutNobel
Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
2011
Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors
2000
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
2008 Standout
Chemical Chaperones Reduce ER Stress and Restore Glucose Homeostasis in a Mouse Model of Type 2 Diabetes
2006 StandoutScience
Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.
2001
Works of S Shack being referenced
Molecular profiling using immunohistochemistry (IHC) and DNA microarray (DMA) as a tool to determine potential therapeutic targets in patients who have progressed on multiple prior therapies
2006
Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria.
1994
Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.
1993
Phenylacetate and Phenylbutyrate as Novel, Nontoxic Differentiation Inducers
1997
Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate.
1994
Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate.
1996
Phenylacetate: a novel nontoxic inducer of tumor cell differentiation.
1992
Frequency of potential therapeutic targets identified by immunohistochemistry (IHC) and DNA microarray (DMA) in tumors from patients who have progressed on multiple therapeutic agents
2006